[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"caloric-restriction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:caloric-restriction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100613880","phase-4-the-impact-of-semaglutide-compared-to-energy-restriction-on-type-2-diabetes-100613880",false,"NCT07272343","The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes","A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular Mechanisms","Inclusion Criteria:\n\n1. Age 18-75 years;\n2. BMI≥25 kg\u002Fm²;\n3. Diagnosed as type 2 diabetes mellitus patients according to the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)\";\n4. HbA1c≤8.5%;\n5. Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs;\n6. Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form.\n\nExclusion Criteria:\n\n1. BMI \\\u003C 25 kg\u002Fm²;\n2. Age \\\u003C 18 years, or \\> 75 years;\n3. History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy;\n4. History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months;\n5. Use of GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, or other related drugs within the past 3 months;\n6. Pregnant or breastfeeding women, or those planning to conceive during the study period;\n7. Patients with severe diseases of important organ systems, such as severe cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, renal insufficiency, hematologic diseases, neurological diseases, or malignancies;\n8. Personal or family history of medullary thyroid carcinoma;\n9. Patients with severe mental disorders or communication barriers that prevent accurate understanding of the study content and compliance with the trial procedures.","ALL","18 Years","75 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.",[27,28,29],"Type 2 Diabetes Mellitus (T2DM)","Semaglutide","Caloric Restriction",[31,32,29],"Type 2 Diabetes Mellitus","semaglutide","RECRUITING","2026-03-31",{"date":36,"type":37},"2026-04-02","ACTUAL",{"date":39,"type":37},"2023-02-10",{"date":41,"type":21},"2026-07-01",{"name":43,"class":44},"Second Affiliated Hospital of Nanchang University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100631322","brahms-bed-rest-and-hypometabolism-study-100631322","NCT07499167","BRAHMS: Bed Rest And HypoMetabolism Study","BRAHMS: Bed Rest And HypoMetabolism Study Integrative Physiological Responses to 10 Days of Bedrest and Caloric Restriction: An Exploratory Pilot Study In 10 Healthy Men.","BRAHMS","Inclusion Criteria:\n\n* Healthy male volunteers (see below the description of medical tests and laboratory analysis performed at the selection visit)\n* Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination): in particular, free from any known chronic disease or any acute mood or eating disorder, infectious disease or cardiovascular, metabolic, neurological, ENT (especially orthostatic hypotension and vestibular disorders), orthopedic or musculoskeletal disorders.\n* 20 to 40 years old\n* 165 to 185 cm\n* Body Mass Index between 20 and 26 kg.m-2\n* Stable body weight in the past 3 months (less than 4% change)\n* Fat Mass Index (FMI), defined as (bodyfat weigh in kg)\u002F(height in m)2: between 3 and 6 kg.m-2, measured by whole-body DEXA\n* Triglyceride level under 1.7 mmol.L-1\n* Normal bone mass density at left hip and lumbar spine: T-score\\>-1.5, measured by DEXA\n* VO2peak\u002FVO2max between 35 and 55 mL.min-1.kg-1\n* Non-smokers\n* No alcohol or drug dependence, no medical treatment on a regular basis\n* Affiliated to a Social Security system and, for non-French resident, holding a European Health Insurance Card (EHIC) or a Global Health Insurance Card (GHIC).\n* Free of any engagement during the study\n* Who agreed to take part in the study and signed the informed consent\n\nExclusion Criteria:\n\n* Any history or presence of clinically relevant chronic disease; any acute infectious disease. Particularly (but not limited to):\n* Symptomatic orthostatic hypotension whatever the decrease in blood pressure, or asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within 3 minutes when changing from the supine to the standing position\n* Personal or family history of thrombosis, genetic mutation for factor V or prothrombin gene\n* Cardiac arrhythmia\n* Hypertension\n* Auto-immune diseases or Raynaud's syndrome\n* History or symptoms of sleep apnea\n* Chronic back pains,\n* Vertebral fracture, scoliosis, or herniated disc,\n* Color-blindness,\n* Self-reported hearing problems or binocular visual acuity under 6\u002F10 after correction\n* Vestibular disorders\n* Drug addiction\n* History of migraines,\n* History of hiatus hernia or gastro-esophageal reflux,\n* History of thyroid dysfunction or diabetes\n* History of head trauma,\n* History of neurological diseases (e.g. epilepsy)\n* History of genetic muscle and bone diseases of any kind\n* Significant history of allergies\n* Significant abnormality in blood tests\n* Positive serology for hepatitis A, hepatitis B, hepatitis C or AIDS (HIV) virus\n* Mood and Eating disorder (current or past), screened with the Hospital Anxiety Depression Scale (HADS), SCOFF (Sick, Control, One, Fat, Food) and the Eating Disorder Examination Questionnaire (EDE-Q)\n* Antibiotics exposure 2 months prior to the study\n* Major lifestyle changes (e.g. significant weight\u002Fbody changes, diet or exercises regimen) 6 months prior to the study\n* Specific diet (e.g vegan, carnivore, intermittent fasting, dietary supplements consumption)\n* History of hypocaloric diet, judged as significant by the investigator\n* Subject who, in the judgment of the investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development,\n* Subject in the exclusion period of another clinical research,\n* Subject who received 6000 Euros or more within 12 months for being a research subject,\n* Poor tolerance to blood sampling,\n* Subject who cannot be contacted in case of emergency,\n* Contraindications for MRI: claustrophobia, presence of osteosynthesis material or metal implants,\n* Blood donation of more than 7 ml\u002Fkg in the 8 weeks prior to the start of the study,\n* Vulnerable people according to law \"Code de la Santé Publique\" (L1121-5 to L1121-8):\n* Pregnant or nursing women (urine pregnancy test for women of childbearing potential)\n* People deprived of their liberty by an administrative or judicial decision\n* People under involuntary psychiatric care\n* People admitted in a health or social establishment for purposes other than research\n* Minors\n* Adults subject to legal protection (subject under guardianship or trusteeship) or unable to express their consent",true,"MALE","20 Years","40 Years",{"count":59,"type":21},10,[61],"NA","The goal of this single arm, interventional monocentric clinical trial is to investigate the physiological effects of a combination of head-down bedrest and caloric restriction on the human body. A set of measurements will assess the changes in the musculoskeletal, cardiovascular, hematological, immune, neurological, cognitive and metabolic systems, in 10 healthy male volunteers.\n\nThe main question it aims to answer is: what are the physiological responses to fasting in a microgravity environment?\n\nIn an exploratory study such as this one, where many physiological systems are explored, it is difficult to select a single important endpoint. However, given the known effect of both caloric restriction and head-down bedrest on muscle loss, and its critical importance for the success of space missions, lean body mass, as assessed by DEXA, was chosen as the primary endpoint.\n\nThe secondary endpoints are:\n\n* Cardiovascular, muscular, neuro-vestibular and neuropsychological functional performance\n* The onset of clinical symptoms and biological changes\n\nParticipants will be exposed to a microgravity analog model (head down bed rest) and controled caloric restriction environment for 10 days, multiple physiological assessments will be performed during this period. Followed by a rehab period before leaving the study.",[64,29],"Microgravity",[64,66],"Caloric restriction","2026-03-23",{"date":69,"type":37},"2026-03-30",{"date":71,"type":37},"2026-03-10",{"date":73,"type":21},"2027-09-21",{"name":75,"class":76},"Centre National d'Etudes Spatiales","OTHER_GOV",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":45},"100586172","the-effect-of-time-restricted-eating-on-glycemic-and-proinflammatory-biomarkers-among-prediabetic-obese-jordanian-adults-aged-18-40-years-old-100586172","NCT06911918","The Effect of Time Restricted Eating on Glycemic and Proinflammatory Biomarkers Among Prediabetic Obese Jordanian Adults Aged 18-40 Years Old","The Effect of Time Restricted Eating on Glycemic and Proinflammatory Biomarkers Among Prediabetic Obese Jordanian Adults Aged 18-40 Years Old: A Randomized Control Study","Inclusion Criteria:\n\n* IR individuals diagnosed with IR by the physicians as indicated by HOMA-IR score\n* female and male, BMI ≥ 30 to 39.9 kg\u002Fm2\n* age between 18 and 40 years\n* stable weight for 3 months before the beginning of the study\n* sedentary lifestyle\n\nExclusion Criteria:\n\n* previous weight loss surgery\n* pregnancy or intent to become pregnant\n* breastfeeding\n* chronic diseases\n* drug therapies that could interfere with the effectiveness of the dietary intervention (e.g., use of corticosteroids, and anti-diabetic drugs)\n* diabetic type 1 and 2 individuals\n* anyone physically active to reduce the influence of confounding covariates",{"count":85,"type":21},120,[61],"Obesity, a global epidemic, significantly contributes to prediabetes, cardiovascular diseases, and other chronic diseases due to its pro-inflammatory nature. This studyl investigates the effects of time-restricted eating (TRE) with calorie restriction (CR), TRE without CR, and CR without TRE on glycemic control and pro-inflammatory biomarkers among prediabetic obese Jordanian adults aged 18-40 years. The study assesses changes in pro-inflammatory biomarkers (IL-1β, TNF-α, IL-6), insulin resistance (HOMA-IR), and body composition over 12 weeks.\n\nParticipants (n=120) will be randomized into four intervention arms: (1) TRE with CR, (2) TRE without CR, (3) CR without TRE, and (4) a control group with no dietary restrictions and no TRE. Biweekly anthropometric assessments will evaluate pro-inflammatory biomarkers and biochemical measures at baseline and the end of the study. The findings will provide insights into the comparative effectiveness of TRE and CR, potentially offering a safe, cost-effective intervention to prevent obesity-induced inflammation, prediabetes, and progression to type 2 diabetes mellitus.",[89,90,91,29,92],"Insulin Resistance","Inflammation Biomarkers","Time Restricted Eating","Obesity (Disorder)",[94,89,95,29,96],"Time restricted eating","Obesity","Inflammation cytokines","NOT_YET_RECRUITING","2025-03-27",{"date":100,"type":37},"2025-04-04",{"date":102,"type":21},"2025-04-05",{"date":104,"type":21},"2025-11",{"name":106,"class":44},"University of Jordan"]